Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y.
Tasaki Y, et al. Among authors: shimura t.
Asia Pac J Clin Oncol. 2024 Aug;20(4):515-521. doi: 10.1111/ajco.14073. Epub 2024 Apr 29.
Asia Pac J Clin Oncol. 2024.
PMID: 38682421